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Abstract
Background: Highly-pathogenic avian influenza virus (HPAIV) and Newcastle disease virus (NDV) are the two most
important poultry viruses in the world. Natural low-virulence NDV strains have been used as vaccines over the past 70 years
with proven track records. We have previously developed a reverse genetics system to produce low-virulent NDV vaccine
strain LaSota from cloned cDNA. This system allows us to use NDV as a vaccine vector for other avian pathogens.
Methodology/Principal Finding: Here, we constructed two recombinant NDVs (rNDVs) each of which expresses the
hemagglutinin (HA) gene of HPAIV H5N1strain A/Vietnam/1203/2004 from an added gene. In one, rNDV (rNDV-HA), the
open reading frame (ORF) of HA gene was expressed without modification. In the second, rNDV (rNDV-HAF), the ORF was
modified so that the transmembrane and cytoplasmic domains of the encoded HA gene were replaced with those of the
NDV F protein. The insertion of either version of the HA ORF did not increase the virulence of the rNDV vector. The HA
protein was found to be incorporated into the envelopes of both rNDV-HA and rNDV-HAF. However, there was an enhanced
incorporation of the HA protein in rNDV-HAF. Chickens immunized with a single dose of either rNDV-HA or rNDV-HAF
induced a high titer of HPAIV H5-specific antibodies and were completely protected against challenge with NDV as well as
lethal challenges of both homologous and heterologous HPAIV H5N1.
Conclusion and Significance: Our results suggest that these chimeric viruses have potential as safe and effective bivalent
vaccines against NDV and. HPAIV. These vaccines will be convenient and affordable, which will be highly beneficial to the
poultry industry. Furthermore, immunization with these vaccines will permit serological differentiation of vaccinated and
avian influenza field virus infected animals.
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Introduction
Avian Influenza (AI) is an economically-important disease of
poultry worldwide. The etiologic agent is a segmented negative-
strand RNA virus in the genus Influenza virus A of the family
Orthomyxoviridae. Avian influenza virus (AIV) strains are divided
into subtypes based on serological reactions of the two surface
glycoproteins, the hemagglutinin (HA) and neuraminidase (NA).
There are 16 different HA (H1-H16) and 9 different NA (N1-N9)
subtypes [1,2]. In addition, AIV strains are further classified into
two different pathotypes, low pathogenic (LP) and highly
pathogenic (HP). Historically, HPAIV of subtypes H5 and H7
have caused severe disease and high mortality in poultry. Since
1996, HPAIV strains of subtype H5N1 have emerged recently in
Asia have caused disease in poultry around the world, resulting in
the culling or death of more than 500 million poultry in more than
62 countries. H5N1 HPAIV also has caused zoonotic infections in
humans, resulting in 406 confirmed cases and 254 deaths to date
[3,4]. The transmission of H5N1 HPAIV from birds to humans
remains a serious threat to public health. Therefore, control of
H5N1 virus infections in poultry is not only important for the
poultry industry, but also for preventing H5N1 infection in
humans.
Traditionally, HPAI is controlled by elimination of infected
flocks. Due to economical reasons, culling of infected flocks is no
longer a practical method for control of AI in either developed or
developing countries. Although vaccination has been recommend-
ed by the World Organization for Animal Health (OIE) and the
Food and Agriculture Organization (FAO) to control AI, few
effective AI vaccines are available [5]. For the most part, these
consist of inactivated preparations of whole influenza viruses.
However, inactivated vaccines are not commonly used because of
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vaccinated animals’’ (DIVA). Live attenuated vaccines are not
used because of concern that the vaccine viruses may, through
either mutation or genetic reassortment with circulating strains,
become virulent [6]. To overcome these difficulties, several
strategies have been developed based on in vivo expression of HA
by DNA vaccines [7,8] or by vectors based on adenovirus
[9,10,11], fowl pox virus [12,13,14,15], baculovirus [16,17,18],
infectious laryngotracheitis virus (ILTV) [19,20], or Newcastle
disease virus (NDV) [21,22,23,24].
Of all AI vaccine strategies, HA protein expressed in vivo using
NDV as a vector has shown the most promising results [21,22,23].
NDV is a non-segmented, negative-strand RNA virus belonging to
genus Avulavirus in the family Paramyxoviridae. Virulent NDV strains
cause a severe respiratory and neurologic disease in poultry world
wide. Naturally-occurring avirulent NDV strains have been
successfully used as vaccines for more than 70 years. Development
of reverse genetic systems has allowed manipulation of the genome
of NDV [25,26,27] and generation of recombinant NDVs that
express foreign proteins from added genes [24,28,29]. Several
groups have used NDV reverse genetic systems to develop vaccines
against AIV subtypes H5 [21,23] and H7 [22].
There have been two independent studies to develop bivalent
vaccines against NDV and HPAI H5 virus [21,23], with different
levels of success. In one study, the HA gene from an H5N2 virus
was inserted between the F and HN genes of NDV [23]. This
recombinant NDV protected chickens against both NDV and
H5N2 virus, but some vaccinated chickens showed signs of clinical
disease when challenged with highly- pathogenic H5N2 virus. In
the other study, the HA gene from an H5N1 virus was inserted
between the P and M genes of NDV [21]. This recombinant NDV
protected chickens against both NDV and two different strains of
H5N1 viruses isolated in China.
In this study, we have attempted to develop improved bivalent
vaccines against NDV and HPAI H5 virus by using recombinant
NDV (rNDV) vaccine strain LaSota as a vector to express the HA
protein from an HPAI H5N1 virus. Two different rNDVs were
constructed expressing different forms of the HA protein: one
vector (rNDV-HA) expressed an unmodified form of HA, while
the other (rNDV-HAF) expressed a version of HA in which the
HA ectodomain was fused with the transmembrane and
cytoplasmic domains derived from the F protein of NDV. This
resulted in a chimeric HA protein with enhanced incorporation of
foreign proteins into NDV particles. The protective efficacies of
both these bivalent vaccines were compared in chickens by
challenge with a lethal dose of highly-virulent NDV and
homologous and heterologous H5N1 HPAIV. Our results showed
that a single immunization with either of the candidate bivalent
vaccines completely protected against both pathogens in chickens.
A further enhanced incorporation of the H5 HA into NDV
particles was observed in rNDV-HAF vaccine than into rNDV-
HA vaccine, indicating a better ability of this virus to induce
neutralization antibody response in chickens.
Results
Generation of rNDVs expressing two versions of the HA
protein of H5N1 AIV
Two different rNDVs were constructed expressing different
versions of the HA protein of HPAIV strain A/Vietnam/1203/
2004, a virus isolated from a fatal human infection [30]. In each
construct, the HPAIV coding sequence was placed under the
control of NDV transcriptional signals and inserted, by reverse
genetics, between the P and M genes in the NDV LaSota avirulent
vaccine strain (Figure 1A). One construct, rNDV-HA, was
designed to express the unmodified HA protein; the other
(rNDV-HAF), was designed to express a chimeric HA protein in
which the ectodomain of HA was fused with the transmembrane
domain and cytoplasmic tail region of the NDV F protein
(Figure 1A, constructs 1 and 2, respectively). Both recombinant
viruses were recovered using the reverse genetics method
described previously [31]. The structure of each HA insert in
the genome of these viruses was confirmed by RT-PCR and
nucleotide sequence analysis (data not shown).
Expression of the native and chimeric forms of the HA
protein by rNDV
The expression of the two versions of the H5 HA protein in DF1
cells infected with rNDV-HA and rNDV-HAF were analyzed by
Western blot using polyclonal chicken H5N1 AIV antiserum
(Figure 1B). Immunoblot analysis detected three bands in lysates of
cells infected with rNDV-HA or rNDV-HAF: these represented (i)
the inactive HA precursor HA0, with an apparent molecular
weight of ,65,000 for rNDV-HA (Figure 1B, Lane 3), and
,66,000 for rNDV-HAF (Figure 1B, Lane 4), (ii) the N-
terminally-derived proteolytic cleavage product HA1 with an
apparent molecular weight of ,40,000 for both viruses, and (iii)
the C-terminally-derived proteolytic cleavage HA2 of apparent
molecular weight ,25,000 for rNDV-HA and ,28,000 for
rNDV-HAF. The differences in apparent size reflected the
different transmembrane and cytoplasmic domains. As expected,
HA was not detected in DF1 cells that were mock-infected
(Figure 1B, Lane 1) or infected with rNDV empty vector
(Figure 1B, Lane 2).
We also used immunofluorescence to localize expression of the
native and chimeric HA proteins in DF-1 cells infected with the
recombinant viruses. Intracellular expression was investigated in
cells that were fixed and permeabilized with Triton detergent
(Figure 1D). Positive staining was observed for cells infected with
rNDV-HA or rNDV-HAF using chicken antiserum for NDV
(Figure 1D, upper panel) or H5N1 AIV (Figure 1D, lower panels).
Incorporation of AIV HA protein into the rNDV virion
The recombinant viruses (rNDV, rNDV-HA and rNDV-HAF)
were partially purified from allantoic fluid by sucrose density
gradient centrifugation. Incorporation of AIV HA into the rNDV
envelope was analyzed by Western blot assay (Figure 1C) and
immunogold electron microscopy (Figure 2). Western blot analysis
of purified viruses with anti H5N1 AIV antibodies did not detect
any bands for rNDV, as expected (Figure 1C, Lane 1), whereas
HA1 and HA2 bands were detected in both rNDV-HA and
rNDV-HAF (Figure 1C, Lanes 3 and 2). The inactive precursor
HA0 that was detected in infected cells (Figure 1B) was not
detected in purified viruses (Figure 1C). There were two-fold more
HA1 and HA2 proteins in virions of rNDV-HAF, compared to
rNDV-HA, as determined by densitometry analysis of the bands.
The band intensities were normalized against NDV HN protein as
an endogenous control. This suggested that fusion of the
transmembrane domain and cytoplasmic tail region of NDV F
protein with the HA ectodomain enhanced incorporation of HA
protein into NDV particles. This was consistent with the results of
immunoelectron microscopy (Figure 2). Antiserum to NDV
directed the deposition of gold particles on the envelopes of
rNDV, rNDV-HA, and rNDV-HAF, as expected (Figure 2, upper
panels). Antiserum to H5N1 AIV directed deposition to the
envelopes of rNDV-HA and rNDV-HAF (Figure 2, lower panel).
As expected, there was no gold particle deposit on the envelope of
rNDV. There was significantly more gold particle deposit on the
NDV Vectored Vaccines for AIV
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protein. (A) Schematic diagram depicting the rNDV LaSota genome with insertion of an added gene engineered to express unmodified HA
(construct 1) or chimeric HA consisting of the HA ectodomain fused to the transmembrane and cytoplasmic domains of the NDV F protein (construct
2). In the inserted sequence, the foreign HA coding sequence was preceded by an NDV gene junction containing gene-end (GE) and gene-start (GS)
transcription signal: this results in the HA ORF being under the control of a set of transcription signals such that it is expressed as a separate mRNA.
(B) Expression and processing of H5 HA and chimeric HA in DF1 cells infected with the respective rNDVs and analyzed by by Western blot analysis
using chicken polyclonal H5N1 AIV antibodies. HA specific bands were not detected in lysates of mock-infected DF1 cells (Lane 1) or cells infected
with rNDV empty vector (Lane 2). In contrast, lysates of cells infected with rNDV-HA (Lane 3) or rNDV-HAF (Lane 4) contained uncleaved inactive
precursor (HA0) and proteolytically cleaved HA1 and HA2/HA2-F proteins. (C) Incorporation of the H5 HA protein in purified rNDV particles, detected
by Western blot analysis. HA-specific bands corresponding to the cleaved HA1 and HA2/HA-F2 species were detected in preparations of purified
particles of rNDV-HA (Lane 2) and rNDV-HAF (Lane 3), but not the empty vector rNDV (lane 1). (D) Immunofluorescence analysis of DF 1 cells infected
with rNDV, rNDV-HA and rNDV-HAF and processed for intracellular expression of NDV proteins (upper panels) and H5 HA protein (lower panel),
detected using chicken polyclonal anti-NDV and anti-H5N1 AIV antibodies.
doi:10.1371/journal.pone.0006509.g001
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anti H5N1 AIV antibodies (Figure 2, lower panel). This suggested
that the chimeric version of the HA protein was incorporated
more efficiently into the NDV envelope than the native HA
protein.
Biological characterization of rNDV expressing the native
or chimeric HA protein
The multicycle growth kinetics of rNDV-HA and rNDV-HAF
were compared with those of the parental rNDV. Our results
demonstrated similar kinetics of growth between rNDV and
rNDV-HA, whereas rNDV-HAF grew more slowly and achieved
a maximal titer that was approximately one log lower than those of
parental rNDV titers (Figure 3A). Similar plaque sizes were
observed for rNDV and rNDV-HA, but a slightly smaller plaque
size was observed for rNDV-HAF (Figure 3B). The pathogenicities
of wild type NDV strain LaSota (wt LaSota) and parental rNDV,
rNDV-HA and rNDV-HAF were evaluated by the mean death
time (MDT) test in embryonated chicken eggs. The MDTs for
these viruses were 105 h (wt NDV), 110 h (rNDV), 112 h (rNDV-
HA) and.120 h (rNDV-HAF). According to OIE guidelines, an
NDV strain is considered lentogenic or avirulent, if the MDT
value is.90 h [32], and thus the two rNDVs expressing the two
versions of HA are avirulent viruses. Indeed, the presence of the
added native or chimeric HA gene conferred attenuation to the
NDV vector.
Immunogenicity and protective efficacy in chickens
against highly-virulent NDV challenge
To evaluate protective efficacy, groups of chickens were
inoculated by the oculonasal route with wt NDV LaSota (the
naturally attenuated vaccine strain that was the parent for the
NDV vectors), or with the recombinant rNDV-HA and rNDV-
HAF viruses, or were left unimmunized as a control group
(Table 1). The birds were challenged 21 days later by the
oculonasal route with highly-virulent NDV strain Texas-GB. All of
the chickens that had been immunized with biologically-derived
wt LaSota, rNDV-HA, or rNDV-HAF were completely protected
from NDV challenge, with no evidence of virus shedding and
without any disease signs (Table 1). In contrast, all of the chickens
in the unvaccinated control group died within 3 days after
challenge (Table 1). Each of the NDV immunizations induced a
substantial titer of NDV-specific HI serum antibodies when
assayed on day 21 prior to challenge. However, the mean antibody
titers induced by rNDV-HA and rNDV-HAF were approximately
one and two log2 less than that of wt NDV, respectively (Table 1).
This modest reduction in immune response to the vector might
Figure 2. Immunoelectron microscopy of purified virions of rNDV, rNDV-HA and rNDV-HAF, analyzed using mouse monoclonal
antibodies against the NDV HN protein (upper panel) or chicken polyclonal antibodies against H5N1 AIV (lower panel).
doi:10.1371/journal.pone.0006509.g002
Figure 3. Multicycle growth kinetics (A) and plaque morphol-
ogy (B) of the rNDV, rNDV-HA and rNDV-HAF viruses in DF-1
cells.
doi:10.1371/journal.pone.0006509.g003
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insertion of the HA gene, as indicated above by the MDT assay, or
might reflect an effect on expression of the NDV HN protein (the
antigen-specificity of the antibodies measured by the HI assay) due
to the presence of the upstream foreign gene, or both.
Protective efficacy in chickens against homologous and
heterologous HPAIV challenge
As a result of genetic drift, there exists considerable antigenic
diversityinthe HAproteinamong H5N1viruses,resulting indistinct
clades and subclades within the HA of the H5N1 lineage viruses.
Currently, two clades are circulating among poultry, namely clade 1
that includes the A/Vietnam/1203/2004 strain represented in the
NDV vectors, and clade 2.2 that includes the A/Egret/Egypt/01/
2006 virus. Therefore, we were interested in evaluating the ability of
the NDV-HA and -HAF vectors to provide protection against
challenge with the clade 1 and clade 2.2 HPAIV.Groups of chickens
were vaccinated with rNDV, rNDV-HA, rNDV-HAF, or were left
unvaccinated. The pre-challenge sera collected at 21 days post-
vaccination had mean NDV HI antibody titers (log2)o f5 . 3 0 60.94,
5.1560.95 and 4.5060.70 for rNDV, rNDV-HA and rNDV-HAF,
respectively (Table 2). Thus, the reduction in NDV-specific
antibodies associated with the presence of the foreign HA gene
was less than in the preceding experiment shown in Table 1. The
mean HPAIV HI serum antibody titers (log2) in birds immunized
rNDV, rNDV-HA or rNDV-HAF were 0, 4.5761.06 and
4.5361.36, respectively, against the homologous A/Vietnam/
1203/2004 virus, and were 0, 2.9261.09, and 2.3861.35,
respectively, against the heterologous A/Egret/Egypt/01/2006
virus (Table 2). The rNDV-HA- and rNDV-HAF-vaccinated birds
were completely protected from intranasal challenge by 100 CLD50
doses of either the homologous or heterologous HPAIV, with no
clinical disease signs or deaths (Table 2). In contrast, all of the
chickens in the unvaccinated control and rNDV-vaccinated (empty
vector) groups died within 24–48 h following challenge with the A/
Vietnam/1203/2004 virus, and within 48–72 h following challenge
with the A/Egret/Egypt/01/2006 virus. The birds that died from
the latter virus had signsof greenishwhite diarrheaand hemorrhagic
signs in the legs and combs.
Shedding of vaccine and challenge viruses in infected
chickens
Shedding of NDV vaccine and HPAIV challenge viruses was
monitored by taking oral and cloacal swab samples on day 3 post-
Table 1. NDV-specific serum antibody responses following immunization with NDV-HA or NDV-HAF and survival of chickens
following virulent NDV strain Texas-GB challenge
1.
Response to immunization Protection of chickens post challenge
2
Chicken group No. of birds seropositive Mean NDV serum antibody HI titer (log2) Oral shedding Cloacal shedding No. of survivors
Uninfected control 0/10 0.00 10/10 4/10 0/10
wtNDV (LaSota) 10/10 6.1860.91 0/10 0/10 10/10
rNDV-HA 10/10 5.5060.70 0/10 0/10 10/10
rNDV-HAF 10/10 4.1060.63 0/10 0/10 10/10
1Chickens in groups of 10 were vaccinated on day 0 with wtNDV, rNDV-HA, or rNDV-HAF. On day 21, serum samples were taken and the birds were challenged with 10
4
ELD50 of virulent NDV strain Texas GB.
2Shedding of challenge virus was determined by inoculation of oropharyngeal (oral) and cloacal swab samples into of embryonated chicken eggs followed by HA tests
of allantoic fluid. All of the uninfected control birds died by day 3, and oral and cloacal samples were taken at the time of death. For the other birds, samples were
taken on day 3.
doi:10.1371/journal.pone.0006509.t001
Table 2. NDV- and HPAIV-specific serum antibody responses following immunization with rNDV-HA and rNDV-HAF and survival of
chickens after homologous and heterologous HPAIV challenge.
Response to immunization (samples taken on 21 day)
Groups: Immunizing virus/
Challenge HPAIV (no. of birds)
1
Mean NDV serum HI
antibody (log2)
No. of birds seropositive
to the indicated HPAIV
Mean serum HI antibody
(log2) to indicated HPAIV
No. of survivors following challenge
on day 21 with the indicated HPAIV
Uninfected/Viet (5) (0)
2 0/5 0 0/5
Uninfected/Egypt (5) 0/5 0 0/5
rNDV/Viet (5) (5.3060.94)
2 0/5 0 0/5
rNDV/Egypt (5) 0/5 0 0/5
rNDV/Viet (10) (5.1560.95)
2 10/10 4.5761.06 10/10
rNDV/Egypt (10) 10/10 2.9261.09 10/10
rNDV/Viet (10) (4.5060.70)
2 10/10 4.5361.36 10/10
rNDV/Egypt (10) 10/10 2.3861.35 10/10
1Chickens in groups of 5 or 10, as indicated, were vaccinated on day 0 with wtNDV, rNDV-HA, or rNDV-HAF. On day 21, serum samples were taken and the birds were
challenged with 100 CLD50 of the indicated HPAIV. Groups are named according to the immunizing NDV vector and the HPAIV strain used in the HI assays and
challenge. Viet=homologous A/Vietnam/1203/2004; Egypt=heterologous A/Egret/Egypt/01/2006.
2Mean of the viruses in #1a n d#2.
doi:10.1371/journal.pone.0006509.t002
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of infectious NDV vector or HPAIV challenge virus was
determined by inoculation of embryonated chicken eggs and
confirmation of virus replication by HA assay. No cloacal shedding
was observed for any of the NDV vaccine viruses post-
immunization, consistent with the attenuated nature of the NDV
vector (Table 3). All of birds immunized with rNDV and rNDV-
HA were positive for oral shedding, but only 14 out of 20 birds
immunized with rNDV-HAF were positive for oral shedding.
Analysis of shedding of NDV vaccine virus was performed to
confirm immunization and its replication in chickens. Although
the exact time at which vaccine virus stopped shedding was not
determined, NDV lentogenic vaccine strains known to shed 5 days
post immunization. Following challenge with homologous or
heterologous HPAIV, no HPAIV shedding was observed in
rNDV-HA- and rNDV-HAF-immunized birds at 3, 5 and 7 days
post-challenge. In contrast, both oral and cloacal shedding of
challenge viruses were observed in all (oral) or most (cloacal) of the
unvaccinated and rNDV (empty vector) -vaccinated birds,
respectively, of the challenge virus. The shedding results of only
day 3 post-challenge are shown in Table 3.
Comparison of pre- and post-HPAIV challenge serum
antibody responses by the DIVA strategy
The pre-challenge sera collected from birds at 21 days post-
immunization with rNDV-HA and rNDV-HAF were compared
with sera collected at 10 days post-challenge with HPAI A/
Vietnam/1203/2004 or A/Egret/Egypt/01/2006 viruses. Un-
vaccinated control and rNDV (empty vector) vaccinated chickens
did not survive the HPAIV challenge, hence pre- and post
challenge comparison was not carried out. The comparison was
carried out using a commercially available AIV NP ELISA that
provides the basis to differentiate between birds vaccinated with an
NDV-based vector (which would not stimulate antibodies against
HPAIV NP) and infected birds (in which an NP-specific response
would occur). Pre- and post-challenge sera also were analyzed by a
commercial NDV ELISA test and an HI assay using the respective
homologous or heterologous HPAIV strain. There was little or no
change in NDV antibody titers detected by NDV ELISA following
HAPIV challenge, as might be expected (Table 4). However, in
both rNDV-HA- and rNDV-HAF- vaccinated birds, the HPAIV
HI titers were increased by one and two log2 units following A/
Vietnam/1203/2004 and A/Egret/Egypt/01/2006 challenge,
respectively. However, both the pre- and post-challenge sera of
rNDV-HA- and rNDV-HAF-vaccinated birds were negative for
AIV NP antibody by AIV NP ELISA. The lack of a detectable
response to the AIV NP protein following HPAIV challenge
suggested that there was little or no challenge virus replication.
Neutralization of diverse HPAIV strains with sera from
birds immunized with NDV-HA or NDV-HAF
The ability of sera from vaccinated chickens (from the study
described in Tables 2–4) to neutralize homologous and heterol-
ogous strains of HPAIV was assessed by virus neutralization (VN)
and HI tests (Table 5). Both rNDV-HA and rNDV-HAF elicited
serum antibodies that reacted with H5N1 clade 1 viruses (A/
Vietnam/1203/2004, A/Hong Kong/213/2006), clade 2.2 virus
(A/Egret/Egypt/01/2006) and an H5N2 virus isolated from
chickens (A/Pennsylvania/8/3/83) by HI tests, and which
neutralized each of these viruses by VN tests. This result indicated
that the antibodies induced by rNDV-HA and rNDV-HAF have
abilities to neutralize a broad range of HPAI H5 subtype viruses.
Discussion
In the past twelve years, HPAI H5N1 viruses have not only
devastated poultry industries but also have become a major public
health concern [3,4].These viruses have shown continuous
increases in genetic and antigenic heterogeneity, as well as
dissemination in Asia, Africa and Europe. In order to limit the
infection of H5N1 viruses in poultry, there is a need to develop
vaccines that provide broad and effective immunity and protection
against these viruses. One vaccine that has shown promising
results is based on using NDV as a vector to express the HPAIV
HA protein from an added gene [21,22,23]. Newcastle disease is
an economically important disease of poultry, and vaccination of
poultry with live NDV vaccines is readily achieved and is
mandatory in many countries. Therefore, development of an
efficacious live bivalent vaccine against AIV and NDV has several
advantages, including price per dose, ease of administration, and
ability to differentiate infected from vaccinated animals.
Our goal is to develop NDV as a vaccine vector for protection
of birds against HPAIV H5 subtype virus infections. Previously,
two research groups have published results describing generation
of NDV recombinant vaccines against HPAI H5 subtype virus
[21,23]. In the present study, we have generated improved
recombinant NDV vaccines that provide greater protection in
chickens against homologous and heterologous HPAI H5 virus
challenges than those previously observed. Veits et al., [23]
generated an rNDV in which the HA gene from an H5N2 virus
was inserted between F and HN genes of NDV clone 30, a
derivative of strain LaSota. Although their rNDV protected
chickens from lethal NDV and highly-pathogenic H5N2 virus
challenges, some vaccinated chickens showed signs of disease when
challenged with H5N2 virus, indicating only partial protection. Ge
et al.,[21] constructed an rNDV in which the HA gene from an
HPAI H5N1 virus isolated from an wild bird in China was
Table 3. Frequency of shedding of the NDV-based vaccine viruses and HPAIV challenge viruses
1.
rNDV-based vaccine virus HPAIV challenge virus
A/Vietnam/1203/2004 A/Egret/Egypt/01/2006
Chicken groups Oral Cloacal Oral Cloacal Oral Cloacal
Uninfected control - - 5/5 4/5 5/5 4/5
rNDV 10/10 0/10 5/5 4/5 5/5 3/5
rNDV HA 20/20 0/10 0/10 0/10 0/10 0/10
rNDV HAF 14/20 0/10 0/10 0/10 0/10 0/10
1From the experiment in Table 2. Shedding was determined by collecting oral and cloacal swabs on 3 day post vaccination and 3 day post challenge and inoculation
into embryonated chicken eggs followed by HA tests for virus growth.
doi:10.1371/journal.pone.0006509.t003
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recombinant virus protected chickens from the disease following
challenges with NDV and homologous and heterologous H5N1
HPAIV. However, the heterologous challenge virus was detected
from the lung, spleen, kidney and brain of one of three chickens at
3 days post-challenge. In that study, both the challenge viruses
used were selected from the same geographic area and having
95% similarity in HA gene. Therefore, there is a need to improve
NDV-vectored AIV vaccines to provide complete protection
against homologous and heterologous challenge viruses isolated
from different geographic areas.
In our study, we have generated two different rNDV expressing
the H5 HA protein. In one rNDV, the HA gene was expressed in
native, unmodified form, while in the other it was modified to
contain the transmembrane and cytoplasmic region of NDV F
protein in place of its own. This was done with the idea that this
would provide for enhanced incorporation into the NDV particle.
The unmodified and modified HA genes were inserted separately
between the P and M genes of NDV strain LaSota. Both of the
recombinant vaccine viruses induced high levels of serum antibody
that efficiently neutralized NDV as well as four different strains of
HPAI H5 subtype viruses, which included three H5N1 viruses
isolated from a humans and one H5N2 virus isolated from a
poultry outbreak in the U.S. Both of the recombinant viruses
completely protected chickens against otherwise-lethal NDV and
HPAI H5N1 virus challenges. The challenge viruses used were
isolated from Vietnam and Egypt. None of the vaccinated animals
shed detectable amounts of challenge virus, demonstrating the
efficacy of our vaccines. Furthermore, none of the vaccinated
chickens had a detectable serum antibody response to the NP
protein of AIV after 10 days of challenge, suggesting that there was
little or no challenge virus replication in vaccinated chickens.
An ideal AI vaccine should elicit robust protective immune
responses against a broad range of homologous and heterologous
H5 influenza strains. Therefore, it is necessary to select the HA
gene from a virus that can represent most H5 strains of that
nature. In our study, we chose the HA gene from A/Vietnam/
1203/2004 virus for generation of recombinant NDV. This H5N1
virus belongs genetically to clade 1 and persists in Asia. The
heterologous H5N1 challenge virus A/Egret/Egypt/01/2006
used in this study belongs to clade 2.2 and persists in Africa.
There is approximately 7% amino acid divergence between the
HA1 portions of the two viruses [33]. Single vaccinations of
rNDV-HA or -HAF completely protected chickens against both
clade 1 and clade 2.2 challenge viruses. Analysis of the pre-
challenge serum neutralizing antibody responses of vaccinated





Mean NDV serum ELISA titer
2a
Mean serum HI antibody (log2)
to the indicated HPAIV
3 Mean HPAIV NP ELISA titer (OD)
4
Pre- Post- Pre- Post- Pre- Post-
rNDV-HA/Viet (10) 1.3960.38 1.3960.38 4.4060.96 5.8060.78 0.07460.012 0.08260.013
rNDV-HA/Egypt (10) 1.2560.37 1.2260.23 2.9061.10 4.9061.42 0.07160.008 0.08460.007
rNDV-HAF/Viet (10) 1.2560.37 1.1960.46 4.4561.78 5.1861.71 0.07160.004 0.08860.033
rNDV-HAF/Egypt (10) 1.1260.42 1.1060.16 2.8061.61 4.9060.73 0.06860.005 0.09560.033
1Continuation of the experiment in Tables 2 and 3.
2Viet=A/Vietnam/1203/2004; Egypt=A/Egret/Egypt/01/2006.
2aCommercial NDV ELISA assay (Synbiotic Corporation, San Diego, CA).
3The challenge virus was used for the HI antibody assays.
4Commercial HPAIV NP ELISA assay (Synbiotic Corporation, San Diego, CA). Negative control OD=0.083 and Positive control OD=0.867.
doi:10.1371/journal.pone.0006509.t004
Table 5. Serum antibodies induced by NDV-HA or NDV-HAF: HI and virus-neutralizing (VNT) antibody titers against homologous
and heterologus HPAIV strains.
Serum antibody titers against the indicated HPAIV strains
Immunizing virus Vietnam/1203/2004 (H5N1) Egret/Egypt/2006 (H5N1) Hongkong/213/2006 (H5N1) Pennsylvania/8/3/1983 (H5N2)
Mean HPAIV HI titer (log2)
1
rNDV 00 00
rNDV- HA 4.5761.06 2.9261.09 5.1960.93 2.9861.28
rNDV- HAF 4.5361.36 2.3861.42 5.1961.23 2.9661.61
Mean VNT titer (log2)
1
rNDV 00 00
rNDV- HA 5.1961.23 2.6060.99 6.7860.93 5.2360.81
rNDV- HAF 5.3061.46 3.1961.47 6.8761.07 5.4261.23
1Sera are from the experiment in Table 2, taken 21 days following a single immunization with the indicated virus expressing the HA of the Vietnam/1203/2004 strain.
The numbers of animals in the groups were: rNDV (n=10), rNDV-HA (n=20), rNDV-HAF (n=20). Note that the text uses VN for virus neutralization, rather than VNT.
doi:10.1371/journal.pone.0006509.t005
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neutralizing activity against the homologous clade 1 virus
compared to the heterologous clade 2.2 virus, which was an
indication of the antigenic differences between the two clades.
Nonetheless, the protection conferred by the NDV-HA and NDV-
HAF vaccine viruses was sufficiently broad to protect against both
HPAIV challenge viruses.
It was previously observed that replacement of the transmem-
brane and cytoplasmic tail regions of the H7 HA protein with
those of the NDV F protein enhanced incorporation of HA into
NDV particles [22]. In that study, enhanced incorporations of the
H7 HA protein into NDV particles improved the immunogenicity
of the virus. However, this result could not be interpreted because
the authors simultaneously change the F protein cleavage site from
a mono-basic to a poly-basic motif, which likely would have the
effect of increasing replication, spread, and immunogenicity.
Nonetheless, only 90% of the vaccinated chickens were protected
against challenge with the HPAIV H7 virus. In our study, we have
followed the same strategy and examined the incorporation of H5
HA protein into NDV particles. Our Western blot and immune
electron microscopy results confirmed that replacement of the
transmembrane and cytoplasmic tail domain of H5 HA protein
with those of the NDV F protein enhanced incorporation into
NDV particles and improved the immunogenicity of the virus by
completely protecting (100%) the chickens against NDV and
HPAI H5 challenges.
Because expression of the H5 HA protein of a highly pathogenic
HPAIV, and in particular its incorporation into the NDV virion,
may alter the virulence of the NDV vector, we examined the
pathogenicity of the recombinant viruses by the MDT method in
embryonated chicken eggs [32]. Our results did not show any
increase in pathogenicity of our recombinant viruses compared to
that of the parent strain LaSota, which is currently used as a
vaccine. However, comparison of growth kinetics of the recom-
binant virus showed that the virus expressing the chimeric H5 HA
protein grew about a log10 lower, than the NDV parent or the
virus expressing the unmodified H5 HA protein. Similar slow
growth kinetics were observed for the virus expressing the chimeric
H7 HA protein [22]. It is possible that enhanced incorporation of
chimeric HA may have affected the assembly process of NDV.
A concern we wanted to examine is whether enhanced
incorporation of the chimeric H5 HA protein may decrease the
incorporation of the NDV F protein into the NDV virion. The F
protein of NDV is a major immunogenic protein and any
reduction in the amount of this protein may alter the efficacy of
the NDV vaccine. Analysis of the proteins of purified parental and
recombinant viruses by coomassie blue staining did not show any
difference in the amount of F protein between parental and
recombinant viruses, suggesting that the incorporation of the
chimeric H5 HA protein did not take the place of the F protein on
the NDV virion (data not shown).
In this study, both of the recombinant NDV vaccine viruses,
rNDV-HA and rNDV-HAF, induced similar levels of HI and VN
antibodies and provided complete protection against challenges
with highly virulent NDV and HPAI H5 viruses. However, further
studies involving larger numbers of chickens and additional
heterologous challenge viruses will be necessary to determine
which of the two vaccine viruses is superior: namely, the NDV-HA
virus that replicates somewhat better but incorporates a lesser
amount of HPAIV HA, or the NDV-HAF virus that replicates less
well (and is more attenuated) but incorporates a greater amount of
HA. Our results demonstrated that the NDV-vectored AIV
vaccines generated in this study could be used as bivalent vaccines
against NDV and HPAI H5 virus in chickens.
Materials and Methods
Viruses and cells
Madin-Darby Canine Kidney (MDCK), human epidermoid
carcinoma (HEp-2), and chicken embryo fibroblast (DF1) cell lines
were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). MDCK and HEp-2 cells were grown
in Eagle’s minimal essential medium (EMEM) containing 10%
fetal bovine serum (FBS) and maintained in EMEM with 5% FBS.
DF1 cells were grown in Dulbecco’s minimal essential medium
(DMEM) with 10% FBS and maintained in DMEM with 5% FBS.
Recombinant NDV (rNDV) strain LaSota was generated as
previously described [31,34]. The HPAIV strains, A/Vietnam/
1203/2004 (H5N1) and A/Hong Kong/213/2006 (H5N1), were
obtained from the Centers for Disease Control and Prevention
(CDC), Atlanta GA. The HPAIV strain A/Egret/Egypt/01/2006
(H5N1) was obtained from Dr. Daniel Perez and the HPAIV
strain H5N2 strain (A/Pennsylvania/8/3/1983) was a field isolate
maintained in our virus repository. The viruses were propagated in
9-day-old specific pathogen free (SPF) embryonated chicken eggs.
Virus titration
The titration of rNDVs and AIVs was carried out by infecting
DF1 and MDCK cells, respectively. The rNDV titers were
determined by plaque assay in DF1 cells using a 0.8% methylcel-
lulose overlay and 5% allantoic fluid. The infected cells were
incubated at 37uC for 3 to 4 days, until the development of plaques
was apparent. The cell monolayers were then fixed with methanol
and stained with crystal violet for the enumeration of plaques. The
HPAIV titers in 50% end point tissue culture infectious dose
(TCID50) units/ml were determined on monolayers of MDCK cells
using the Reed and Muench method [36]. For both NDVs and
AIVs, HA titers were determined using chicken RBCs [32]. Egg
infective dose 50 (EID50) was determined by infecting 5 eggs per
group for each 10-fold serial dilution. Following 24 h of infection,
eggs were harvested for allantoic fluid and the presence of virus was
confirmed by HA test. Similarly, chicken embryo lethal dose 50
(ELD50) was determined by observing 50% mortality in embryos at
end point dilutions after 48 h of infection. The 50% end point titer
wasdeterminedbytheReed andMuenchmethod [36].ForHPAIV
challenge viruses, the chicken lethal dose of 50 (CLD50) was
determined by infecting 3 chickens (5-wk-old) per group, and the
50% end point for the lethal dose was determined by the Reed and
Muench method [36].
Generation of rNDVs containing HPAIV HA coding
sequence
The construction of a full-length cDNA of the antigenomic
RNA of NDV strain LaSota was reported earlier [31,34]. The
present study used a previously-described derivative that had been
modified to contain a unique Pme I restriction enzyme site
between the P and M genes [31]. The HA open reading frame
(ORF) from HPAIV strain A/Vietnam/1203/2004 (H5N1) virus
was PCR-amplified using primers (H5HAPmeI sense- 59-
CCGTTTAAACTTA GAAAAAATACGGGTAGAAGGCATA
CGCCACCAT GGAG-39 and antisense 59-GGGTTTAAACT-
TAGATACAAATCCT GCACTGG-39) that introduced an NDV
gene junction, including gene end (underlined), intergenic, and
gene start (underlined) signals, on the upstream side and Pme I
sites (italic) on both sides. The H5 HA gene was further modified
to create a second version in which the HA ectodomain was fused
to the transmembrane and cytoplasmic domains of the NDV F
protein by overlapping PCR using primer H5HAPmeI sense and
H5HAF antisense primer (59-GGGTTTAAACTTAGATACAA-
NDV Vectored Vaccines for AIV
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lapping PCR were amplified by H5HA PmeI sense primer
and antisense primer (59- GTAATGAGAGCAGATGTG-
CTTTGGTATATCCCTATGCTCTCC-39, region correspond-
ing HA is underlined) from H5 HA template and also ampli-
fied by sense primer (59-GGAGAGCATAGGGATATAC-
CAAAGCACATCTGCTCTCATTAC-39, region corresponding
NDV is underlined) and H5HAF antisense from NDV F cDNA
template. Altering the transmembrane and cytoplasmic domains
changed the length of the HA ORF from 1707 nt to 1767 nt. The
PCR products were cloned into full- length NDV plasmid at the
unique Pme I site between the P and M genes. The total genome
length was maintained as a multiple of six, which is required for
efficient NDV replication [35]. In order to decrease the possibility
of any mutation or deletion of parts of the NDV genome during
propagation in bacteria, the transformed bacteria were grown at
30uC. The HA genes of the resulting plasmids, pNDV-HA and
pNDV-HAF, were sequenced to confirm the correct HA gene
structure and the absence of any deletion or undesired mutation.
Our results showed that the plasmids pNDV-HA and pNDV-HAF
were quite stable in bacteria and no mutation or deletion was
detected. The NDV recombinants were recovered by transfecting
these plasmids along with support plasmids into HEp-2 cells by the
previously described procedure [31,34].
Expression of H5 HA in cells infected with rNDVs
The HA protein expression by the rNDVs was examined by
Western blot and immunofluorescence assays. DF1 cells were
infected at a multiplicity of infection (MOI) of 0.01 and were
harvested at 48 h post- infection, lysed and analyzed by Western
blot using polyclonal chicken H5N1 (post-infection) antiserum. To
examine the incorporation of H5 HA and H5 HAF into NDV
particles, Western blot analysis was carried out using purified virus
and polyclonal chicken H5N1 (post-infection) antiserum. The
band intensities in the western blot were normalized using an
NDV-HN monoclonal antibody. Immunofluorescence assays were
performed to evaluate cell surface and intracellular expression of
HA protein. Briefly, DF1 cells were infected with the recombinant
viruses at an MOI of 0.01 PFU. At 48 h post-infection, the
infected DF1 cells were fixed with 4% para-formaldehyde. For
internal H5 HA expression, cells were permeabilized with 0.2%
Triton X 100 in PBS for 10 minutes. The primary antibodies used
were chicken polyclonal anti-H5 HA and the secondary antibodies
used were goat anti-chicken conjugated with FITC. The cells were
analyzed with a fluorescent microscope.
Immunoelectron microscopy
The rNDVs purified by sucrose density gradient from allantoic
fluid of infected embryonated eggs were adsorbed to parlodion-
filmed carbon-coated nickel grids. The grids were blocked in PBS
containing 2% globulin-free BSA and incubated with chicken anti-
NDV HN monoclonal antiserum or chicken anti-H5 HA
polyclonal antiserum. Grids were washed in blocking solution
and incubated in goat anti-chicken or anti- mouse IgG antiserum
conjugated to 6 nm gold beads (Aurion, Costerweg 5, The
Netherlands). The grids were then negatively stained with 2%
ammonium molybdate for 3 min and examined under a
transmission electron microscope.
Growth characteristics of the recombinant viruses in DF1
cells
The growth kinetics of rNDV, rNDV-HA and rNDV-HAF
were determined by multicycle growth curves in DF1 cells. DF1
cells in duplicate wells of six-well plates were infected with viruses
at a MOI of 0.01 PFU. After 1 h of adsorption, the cells were
washed with DMEM and then covered with DMEM containing
5% FBS and 5% allantoic fluid. The cell culture supernatant
samples were collected and replaced with an equal volume of fresh
medium at 8-hour intervals until 64 hours post-infection. The
titers of virus in the samples were quantified by plaque assay in
DF1 cells.
Pathogenicity of recombinant viruses in embryonated
chicken eggs
The pathogenicity of the recombinant viruses were determined
by the MDT test in 9- day-old embryonated chicken eggs
according to a standard protocol [32]. Briefly, 10-fold serial
dilutions of fresh infective allantoic fluid ranging from 10
26 to
10
29 dilutions were made with sterile PBS. 0.1 ml of each diluent
was injected into the allantoic cavities of five 9-day-old SPF
embryonated chicken eggs (Bee Eggs Company, PA) and
incubated at 37uC. Each egg was examined three times daily for
7 days, and times of embryo death were recorded. The minimum
lethal dose is the highest virus dilution that causes all embryos
inoculated with that dilution to die.
Immunization and challenge experiments
In experiment one (Table 1), groups of 2-week-old SPF chickens
were immunized through the oculonasal route with 10
6 EID50 of
biologically-derived wild type NDV LaSota or recombinant virus
rNDV (empty vector), rNDV-HA or rNDV-HAF, and an
additional group of birds was left uninfected. Three days post-
immunization, oropharyngeal (oral) and cloacal swabs were
collected for detection of NDV shedding. Three weeks post-
immunization, pre-challenge serum samples were collected from
all of the birds, and all of the birds were challenged with 10
4
ELD50 of virulent NDV strain Texas-GB through the oculonasal
route. Oral and cloacal swabs were collected on day 3 post-
challenge for shedding. In experiment two (Tables 2–5), groups of
birds were immunized in the same way except that the
biologically-derived LaSota control was replaced by its recombi-
nant version rNDV. Three weeks post-immunization, serum
samples were collected and the animals were challenged through
the intranasal route with 100 CLD50 of the homologous HPAIV
A/Vietnam/1203/2004 virus or the heterologous HPAIV A/
Egret/Egypt/01/2006 virus. To monitor shedding of the
challenge viruses, oral and cloacal swabs were collected on day
3 post-infection. Isolation of NDV vaccine vector or HPAIV
challenge virus from swabs was carried out by inoculation in 9-
day-old embryonated chicken eggs. The chickens were observed
daily for 10 days for disease symptoms and mortality, and the
presence of NDV or HPAIV was confirmed by HA assay using
chicken erythrocytes. Post-challenge serum was collected from the
surviving birds before sacrifice after 10 days of challenge. All
challenge studies were performed in a BSL3 (Ag) containment
facility certified by the USDA and CDC.
Serological analysis
The antibody levels of serum samples collected from chickens
vaccinated with rNDVs were evaluated by hemagglutination (HA),
HA inhibition (HI), virus neutralization (VN) and enzyme-linked
immunosorbent assays (ELISA) using standard protocols [36].
Cross-reactivity of immunized chicken sera were conducted by VN
and HI tests against four homologous and heterologous strains of
influenza viruses. The homologous clade 1 H5N1 strains included
(A/Vietnam/1203/2004 and A/Hongkong/213/2006), and het-
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01/2006) and the H5N2 virus (A/Pennsylvania/8/3/1983). A
commercial AIV NP ELISA kit and NDV ELISA kit (Synbiotic
Corporation, San Diego, CA) were used to detect antibodies
against the NP antigen of type A influenza viruses and whole NDV
antigen of NDVs.
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